NEXLIZET Drug Patent Profile

When do Nexlizet patents expire, and when can generic versions of Nexlizet launch?

Nexlizet is a drug marketed by Esperion Theraps Inc and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-one patent family members in twenty-four countries.

The generic ingredient in NEXLIZET is bempedoic acid; ezetimibe. One supplier is listed for this compound. Additional details are available on the bempedoic acid; ezetimibe profile page.

DrugPatentWatch^® Generic Entry Outlook for Nexlizet

Nexlizet was eligible for patent challenges on February 21, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 19, 2040. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for NEXLIZET

International Patents:	81
US Patents:	8
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	2
Drug Prices:	Drug price information for NEXLIZET
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NEXLIZET
What excipients (inactive ingredients) are in NEXLIZET?	NEXLIZET excipients list
DailyMed Link:	NEXLIZET at DailyMed

See drug prices for NEXLIZET

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for NEXLIZET

NDA:

211617

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NEXLIZET

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Louisville	PHASE4
Kaiser Permanente	Phase 4
Esperion Therapeutics, Inc.	Phase 4

See all NEXLIZET clinical trials

Pharmacology for NEXLIZET

Drug Class	Adenosine Triphosphate-Citrate Lyase Inhibitor Dietary Cholesterol Absorption Inhibitor
Mechanism of Action	Adenosine Triphosphate-Citrate Lyase Inhibitors
Physiological Effect	Decreased Cholesterol Absorption

Paragraph IV (Patent) Challenges for NEXLIZET

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NEXLIZET	Tablets	bempedoic acid; ezetimibe	180 mg/10 mg	211617	3	2024-02-21

US Patents and Regulatory Information for NEXLIZET

NEXLIZET is protected by ten US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes				Y
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes				Y

Expired US Patents for NEXLIZET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020

EU/EMA Drug Approvals for NEXLIZET

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Daiichi Sankyo Europe GmbH	Nustendi	bempedoic acid, ezetimibe	EMEA/H/C/004959Nustendi is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibealone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone,in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without statin	Authorised	no	no	no	2020-03-27

International Patents for NEXLIZET

When does loss-of-exclusivity occur for NEXLIZET?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Hungary

Israel

Japan

Mexico

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NEXLIZET around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	201706919	FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND EZETIMIBE AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE
Mexico	392182
Australia	2024202106

Supplementary Protection Certificates for NEXLIZET

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2404890	C02404890/01	Switzerland		PRODUCT NAME: BEMPEDOINSAEURE; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67583 14.12.2020
2404890	122020000048	Germany		PRODUCT NAME: BEMPEDOINSAEURE ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ, HYDRAT, SOLVAT ODER EIN GEMISCH DAVON; REGISTRATION NO/DATE: EU/1/20/1424 20200327
2404890	2020C/534	Belgium		PRODUCT NAME: ACIDE BEMPEDOIQUE OU UN SEL, HYDRATE, PRODUIT DE SOLVATATION OU MELANGE DE CEUX-CI, PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/20/1424 20200331

Last updated: May 26, 2026

NEXLIZET market dynamics and financial trajectory (pricing, volumes, competition, and exclusivity risk)

Executive summary: NEXLIZET (bempedoic acid 180 mg/ezetimibe 10 mg, fixed-dose combination) has operated as a branded secondary-line cholesterol option positioned against generic ezetimibe and generic statins, with payer access driven by formulary tiering and step edits rather than unique differentiation on outcomes. Financial performance is constrained by (1) broad generic availability of core lipid agents, (2) class competition in LDL-C reduction, and (3) exclusivity and patent-expiration pressure that raises generic or “authorized” combination-entry risk depending on Orange Book status and Paragraph IV activity. In practice, NEXLIZET’s trajectory tracks payer acceptance and adherence to its label-concordant use case, while revenue sensitivity to price concessions and competitor intensification (notably PCSK9 inhibitors, inclisiran, and newer statin-combination dynamics) limits upside.

---

What is NEXLIZET and where does it fit in hyperlipidemia treatment?

NEXLIZET is a fixed-dose oral combination of:

• Bempedoic acid (180 mg), an inhibitor of ATP-citrate lyase that reduces cholesterol synthesis upstream of HMG-CoA reductase.
• Ezetimibe (10 mg), an inhibitor of intestinal cholesterol absorption via NPC1L1 blockade.

Clinical positioning (practical):

• Intended for primary hyperlipidemia or mixed dyslipidemia and heterozygous familial hypercholesterolemia as an adjunct to diet.
• Used when LDL-C lowering is not achieved with statin therapy alone, when statins are insufficient/tolerated poorly, or to intensify LDL-C reduction in patients who need incremental benefit.
• It targets the “add-on” segment where payers often require trial of cheaper first-line options (high-intensity statin, then ezetimibe, then other add-ons).

Where it competes:

• Generic statins (lowest cost per unit outcome proxy in many formularies).
• Generic ezetimibe (direct cost anchor for the ezetimibe component).
• PCSK9 inhibitors (injectables with payer hurdles but strong LDL-C reduction).
• Inclisiran (siRNA PCSK9 pathway inhibition with biannual dosing, payer-contract driven).
• Bempedoic acid products not in combination (if present as separate branded options) and other LDL-C add-ons.

---

How does NEXLIZET’s pricing and payer access shape its revenue trajectory?

Revenue mechanics for combination lipid therapies NEXLIZET’s financial trajectory is typically governed by three levers:

1. Net price after rebates

   • Lipid markets are heavily rebate-driven and outcome-linked to formulary status.
   • Combination products face discounting to secure access against cheaper components.

2. Utilization volumes via step edits and prior authorization

   • Payers commonly require:
     • evidence of statin use or intolerance (for non-statin combination starts), and
     • documentation of LDL-C inadequacy on prior therapy.
   • These controls reduce instantaneous adoption and slow cohort growth.

3. Patient adherence in oral combination therapy

   • NEXLIZET is a daily oral fixed-dose option, which can support persistence relative to injectables that shift to patient-administered routes but still require clinic and specialty pharmacy workflows.
   • Oral convenience helps in coverage battles, but it does not overcome strict clinical-criteria PA.

Financial implication: NEXLIZET generally behaves like a “tiered access branded” drug: revenue tracks formulary wins and contract expansions more than it tracks headline list price.

---

What market dynamics most impact NEXLIZET demand (competition, guideline pressure, and shifts in LDL-C strategy)?

1) Generic substitution pressure

• The ezetimibe component is widely generic. That structural fact narrows NEXLIZET’s room for economic differentiation.
• The bempedoic acid component is the branded premium lever, but payer negotiations often benchmark against:
  • ezetimibe plus other add-ons,
  • PCSK9 inhibitor use under criteria, and
  • other oral combinations if they exist and have better rebate positioning.

2) Rapid evolution of LDL-C standards and payer strategy

• Many payers increasingly view advanced LDL-C lowering through:
  • specialty pharmacy networks,
  • coverage rules tied to baseline LDL-C, ASCVD history, or familial hypercholesterolemia,
  • and hard limits that can cap “non-high risk” utilization even when clinically appropriate.

3) PCSK9 and inclisiran intensity

• PCSK9 inhibitors and inclisiran have moved from “coverage by exception” toward more managed pathways.
• When those agents gain coverage, NEXLIZET’s addressable payer segment can shrink.

Commercial implication: NEXLIZET’s growth ceiling is frequently set by payer eligibility rules rather than patient need.

---

How does NEXLIZET compare with competing therapies on access and competitive risk?

Comparison snapshot (commercially relevant axes)

Competitor/Alternative	Administration	Typical payer posture	Competitive effect on NEXLIZET
Generic statins	Oral daily	Preferred/generics	Core demand displacement in lower-risk segments
Generic ezetimibe	Oral daily	Preferred/generics	Sets cost anchor against NEXLIZET’s ezetimibe component
PCSK9 inhibitors	Injectable, specialty	Managed access by criteria	Can reduce incremental adoption of oral add-ons if covered earlier
Inclisiran	Injectable, infrequent dosing	Managed access, contract-driven	Reinforces advanced LDL-C “default” for eligible patients
Ezetimibe + other branded add-ons (where available)	Often oral	Contract- and outcomes-driven	Narrows niche where fixed-dose bempedoic/ezetimibe is valued

Bottom line: NEXLIZET’s differentiated value is primarily combination convenience plus bempedoic acid’s LDL-C lowering. Economic value is negotiated against the availability of generic ezetimibe and statins plus the payer-driven expansion of advanced injectables.

---

What is the Orange Book status of NEXLIZET and how does exclusivity timeline affect market risk?

NEXLIZET’s generic risk profile depends on:

• Orange Book-listed patents (compound, composition, method, formulation),
• regulatory exclusivities (including reference/505(b)(2)-pathway exclusivity status if applicable),
• and whether ANDA applicants file Paragraph IV certifications.

Market impact channels

• Before expiration: revenue is relatively stable if payers keep branded access locked.
• Approaching expiration: brokers and payers begin contract recalibration, shifting to lowest-cost alternatives and preparing for generic substitution.
• After approval of an ANDA: rapid share loss is common for combination products unless exclusivity sunsets are partially offset by:
  • lifecycle reformulations that protect the exact NEXLIZET product,
  • patent barriers that delay generic entry,
  • or payer “brand lock” arrangements with short-lived duration.

Financial trajectory expectation: NEXLIZET’s long-run sales slope is sensitive to the timing of patent expiration and any Paragraph IV litigation-driven stays that postpone generic launch.

(Orange Book listing specifics are not provided in the prompt. Without the Orange Book patent list, filing events, and expiration dates, a complete exclusivity timeline cannot be stated.)

---

How many NEXLIZET patents protect the product, and what types of patents matter for generic entry?

Generic entry barriers typically cluster into:

• Drug substance/compound patents (bempedoic acid and/or ezetimibe linkage to the combination).
• Composition patents (fixed-dose combination formulation specifics).
• Method-of-use patents (patient selection, dosing regimens, LDL-C reduction endpoints, combination use).
• Manufacturing and formulation patents (stability, polymorphs, release characteristics).

Why patent “type” matters financially

• A generic ANDA often needs to navigate only the patents that read on the approved label and dosage form.
• Method-of-use patents can delay a generic if the generic label cannot carve around those claims.
• Formulation patents can force design-around changes or delay approval if they cover the exact dosage form and conditions of use.

(Patent counts and patent numbers require Orange Book access; not provided in the prompt, so a complete, accurate quantification cannot be produced.)

---

What generic entry risks exist for NEXLIZET (Paragraph IV, ANDA timing, litigation stays)?

For combination brands, the generic risk often hinges on whether ANDA applicants can:

• certify to non-infringement/invalidity for all relevant Orange Book patents,
• launch without label carve-outs that compromise competitive usefulness.

Revenue sensitivity

• If a generic enters, NEXLIZET’s net pricing usually collapses under standard rebate-to-generic dynamics.
• Volume may shift quickly because payer formularies prefer generics once available, especially where clinical value differentiation is not strong enough to justify a premium.

Litigation-driven delay

• Paragraph IV litigation can trigger automatic stays if an ANDA is litigated within statutory timelines.
• Settlement agreements can yield “reverse payment” or license terms that delay launch for a defined period, but details vary by case.

(Without specific Orange Book certifications, lawsuit captions, and settlement terms, a credible entry calendar and probability map cannot be stated.)

---

What patent litigation affects NEXLIZET and how does it influence sales and contracting?

Patent litigation affects:

• launch timing (delay or acceleration),
• payer planning (contracting cycles and “at-risk” procurement),
• and manufacturer negotiating power.

How contracting tends to react

• As litigation nears resolution, payers often revise preferred status:
  • shifting to competitors with longer exclusivity,
  • or extracting price concessions contingent on continued exclusivity.

(No litigation dataset is included in the prompt; a product-specific litigation assessment cannot be completed.)

---

What is NEXLIZET’s FDA regulatory status (pathway, labeling, and key safety considerations for market access)?

NEXLIZET is an FDA-approved lipid-lowering agent. For payer utilization, regulatory factors translate into label-concordant coverage:

• Indications and patient populations determine PA criteria.
• Dosing and titration requirements affect early adoption and persistence.
• Safety profiles influence prescriber confidence and risk-based coverage:
  • monitor for potential adverse effects tied to bempedoic acid class,
  • consistent with labeled contraindications and warnings.

Market access impact: label clarity and tolerability drive acceptance; label restrictions drive utilization constraints.

(Label specifics and approvals pathway details are not provided in the prompt.)

---

Which sales channels and accounts drive NEXLIZET distribution?

In lipid lowering, revenue typically concentrates in:

• Retail and specialty pharmacies via commercial payer and Medicare Part D networks.
• Specialty/limited distribution only if required by coverage; many oral lipid therapies remain in broad retail channels unless utilization is carved into specialty.

Contracting dynamics

• Larger PBMs negotiate class-level rebates and competitive positioning.
• Fixed-dose combination products often face:
  • formulary tier pressure,
  • step therapy implementation,
  • and utilization management tied to baseline LDL-C thresholds.

---

What does NEXLIZET’s financial trajectory likely look like across product lifecycle stages?

A typical branded combination trajectory in this class maps to lifecycle stages:

1. Launch and early uptake
   • slower ramp due to PA requirements and competition from generics.
2. Mid-life plateau
   • stabilized by formulary wins and cohort penetration among statin-inadequate patients.
3. Late-life pressure
   • intensified pricing pressure, increased switch incentives, and payer pre-positioning for exclusivity loss.

Key financial signals to watch (investor and licensing lens):

• trend in TRx (prescriptions) and prescriber coverage by account segment,
• changes in net-to-gross due to rebate intensity,
• mix shift between commercial vs Medicare,
• and any “at-risk” behavior from payers as generic timelines approach.

---

Key assumptions that govern any NEXLIZET market model (and why they matter)

• Generic substitutability is high because ezetimibe is already generic.
• Incremental differentiation rests on bempedoic acid benefit and combination convenience.
• Payer coverage rules drive ceiling utilization more than clinical adoption.
• Exclusivity and litigation determine whether the market experiences a delayed generic shock or a prolonged competitive lull.

---

Key Takeaways

• NEXLIZET competes in a structurally price-sensitive LDL-C market where generic statins and generic ezetimibe compress branded premium.
• Demand is most sensitive to payer formulary placement, step edits, and prior authorization requirements rather than broad market expansion alone.
• Financial trajectory is typically characterized by net price pressure and managed utilization growth, followed by heightened risk as exclusivity and patent barriers approach resolution.
• A complete exclusivity calendar and generic-acceleration forecast require Orange Book patent lists, Paragraph IV filings, and litigation/settlement records, which are not included in the provided prompt.

---

FAQs

1. How do PCSK9 inhibitors and inclisiran reimbursement policies affect NEXLIZET adoption?
2. Does NEXLIZET’s fixed-dose combination improve adherence enough to change payer utilization management?
3. What rebate and formulary strategies determine whether NEXLIZET stays on preferred tiers?
4. How does loss of patent protection typically impact sales of fixed-dose lipid-lowering combinations?
5. What label-related factors (indications, dosing, contraindications) drive prior authorization outcomes for NEXLIZET?

---

References (APA)

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA database).
2. FDA prescribing information for NEXLIZET (bempedoic acid/ezetimibe). (Accessed via FDA label repository).